Pharma Journalist -

Pardes Biosciences, Inc., a clinical-stage biopharmaceutical company today announced the initiation of a Phase 1 clinical trial, evaluating the company’s lead candidate, PBI-0451 which…
Read More...

The Only Conference Dedicated to the Development of Cannabinoid Pharmaceuticals There are few therapeutics containing cannabinoids that have been approved by major regulatory…
Read More...

Eagle Pharmaceuticals, Inc. announced that it has entered into a worldwide licensing agreement with Combioxin SA (“Combioxin”), a clinical-stage biotechnology company based in…
Read More...

Eli Lilly and Company and Lycia Therapeutics, Inc. announced a multi-year research collaboration and licensing agreement focused on the discovery, development and commercialization of…
Read More...

Pfizer Inc. and BioNTech SE announced the initiation of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for the approval of a booster…
Read More...

Provectus Algae (Provectus), an Australian biotechnology platform company specialising in the biomanufacturing of high-value compounds for a wide array of industries using microalgae,…
Read More...

FSD Pharma Inc. a life sciences holding company dedicated to building a portfolio of assets and biotech solutions in legal psychedelics and medical cannabis, announces today it has…
Read More...

Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced a multi-target strategic collaboration and…
Read More...

FLEXcon Company, Inc., an innovator in adhesive coating and laminating, today announced the relaunch of its FLEXcon PHARMcal line of track and trace solutions featuring engineered films…
Read More...

AbbVie announced the European Commission (EC) approved RINVOQ (upadacitinib), an oral, selective and reversible JAK inhibitor, for the treatment of moderate to severe atopic dermatitis…
Read More...